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OBJECTIVES: The objective of this study was to evaluate the relationship between the treatment of Helicobacter
pylori gastric infection and changes in best-corrected visual acuity and macular detachment in patients with chronic
central serous chorioretinopathy.
METHODS: Seventeen patients diagnosed with central serous chorioretinopathy were examined for gastric infection
with Helicobacter pylori using the urease test and gastric biopsy. Helicobacter pylori-positive patients were treated
with the appropriate medication. The response to therapy was monitored by evaluating the best-corrected visual
acuity and optical coherence tomography. The data were analyzed using Student’s t-test before and after
treatment.
RESULTS: Fourteen patients (15 eyes) aged 30-56 years (mean 43.4¡8.3 years) were positive for Helicobacter pylori.
Most of the positive patients had gastric symptoms (78.5%); one had bilateral central serous chorioretinopathy. The
mean baseline best-corrected visual acuity was 20/98 (logMAR=0.53¡0.28). Three months after starting treatment
with antibiotics, the serous detachment had resolved in 14 of 15 eyes, but two cases required laser treatment. The
follow-up period ranged from 6 to 27 months. The mean final best-corrected visual acuity differed significantly from
baseline.
CONCLUSION: Our findings suggest that Helicobacter pylori infection may be present in many chronic central serous
chorioretinopathy patients and that treatment for the infection may have a favorable effect on the outcome of
chronic central serous chorioretinopathy. Due to the possibility of the spontaneous regression of chronic central
serous chorioretinopathy and the high prevalence of the infection in the general population, prospective and
masked clinical trials are necessary to confirm that treatment for Helicobacter pylori infection may benefit patients
with chronic central serous chorioretinopathy.
KEYWORDS: Risk Factors; Central Serous Chorioretinopathy; Helicobacter Pylori; Treatment; Macula.
Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA. Helicobacter pylori as a potential target for the treatment of central serous
chorioretinopathy. Clinics. 2012;67(9):1047-1052.
Received for publication on May 1, 2012; First review completed on May 17, 2012; Accepted for publication on May 17, 2012
E-mail: mcasella@sercomtel.com.br
Tel.: 55 43 3324-1177
INTRODUCTION
Central serous chorioretinopathy (CSC) causes a serous
neurosensory detachment of the macula associated with one
or more idiopathic leaks at the level of the retinal pigment
epithelium (RPE). It predominantly affects male adults aged
40-60 years (1,2). Although the condition spontaneously
improves in at least 90% of those affected, recurrence affects
approximately one third of patients (3). Among patients
with CSC, the chronic form of central serous chorioretino-
pathy (CCSC) is defined as the repeating variant of the
disease or diffuse retinal pigment epitheliopathy for more
than six months (4,5). These patients are difficult to treat,
with the most successful modality appearing to be photo-
dynamic therapy (PDT) guided by optical coherence
tomography (OCT). However, patients may lose vision
due to atrophic changes in the RPE/photoreceptor layer (5).
The potential risk factors for CSC include hypertension,
pregnancy, allergic respiratory disease, antibiotic or alcohol
use, corticosteroid therapy and sympathomimetic drugs
(1,2,6-8). A correlation between CSC and infection with
Helicobacter pylori (HP) was recently suggested (9-15). In a
prospective pilot study of 16 patients with CSC and diffuse
retinal pigment epitheliopathy, the prevalence of Helicobacter
pylori infection was significantly higher in patients with CSC
than in the general population (10). The prevalence was
also significantly higher in CSC patients than in a control
population from the same country (11). Other studies also
demonstrated this correlation (14,15). One recent article
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found good outcomes in patients with CSC and receiving
treatment for HP eradication therapy (16). Thus, the objective
of the present study was to assess the best-corrected visual
acuity (BCVA) and macular detachment using OCT in
patients with CCSC who were receiving conventional drug
therapy to treat HP infection.
MATERIALS AND METHODS
This was an interventional, non-blinded case series of
patients with proven chronic CSC. The study was approved
by the research ethics committee of the State University of
Londrina, and all patients provided informed written
consent. CSC was defined as an idiopathic leakage at the
level of the retinal pigment epithelium leading to the
accumulation of subretinal fluid. Subjects diagnosed with
long-lasting (.6 months) or recurring (2 or more times over
the preceding 12 months) CSC and serous macular detach-
ment involving the fovea were followed by the authors from
September 2003 to November 2008. Twenty patients were
invited to participate in the study, but only 17 accepted.
None of the subjects used corticosteroids or sympathomi-
metic drugs or had a systemic disease associated with CSC.
The patients had a complete ophthalmological examina-
tion, including best-corrected Snellen visual acuity (BCVA),
slit-lamp biomicroscopy, tonometry, indirect binocular
ophthalmoscopy, optical coherence tomography (time
domain OCT: Stratus OCT-3000; Carl Zeiss Meditec,
Dublin, CA, USA) and, in the absence of confirmed or
suspected allergy and clinical contraindication, fluorescein
angiography. Patients with clinically and image-confirmed
serous detachment were asked about gastric symptoms and
referred for HP screening with urease tests and gastric
biopsy by endoscopy when the urease test was negative
(17).
HP-positive patients were treated with a combination of
clarithromycin (500 mg twice a day), amoxicillin (1 g twice a
day) and lansoprazole (30 mg twice a day) for seven days.
The treatment was prescribed and followed by a gastro-
enterologist who performed the endoscopic examination of
the upper digestive tract. Following drug therapy, patients
underwent complete ophthalmological examinations at 30-
day intervals to assess visual acuity and ocular status. OCT
images were used to assess the resolution of disease
(absence of subretinal fluid). The follow-up period ranged
from 6 to 27 months. A second endoscopic examination and
gastric biopsy was performed three months after drug
therapy to confirm the eradication of the bacteria. Follow-up
was continued through November 30, 2008, or ended when
the patient decided to undergo another treatment. The
variables are presented in a descriptive form. Student’s
paired t test was used to compare the baseline and end-
point BCVA values, and p-values,0.05 were considered to
be statistically significant.
RESULTS
The study population consisted of three women and 14
men. Eighteen eyes of 17 patients, aged 30-56 years (mean:
43.4¡8.7 years), were studied. The follow-up period varied
from six to 27 months (mean 15¡8.1 months). Fifteen eyes
tested positive for HP. Table 1 shows the patients according
to age, gender, the affected eye, disease duration, the
presence of gastric symptoms, HP examination and visual
acuity at baseline and after treatment. One case (Case 2)
presented with bilateral CCSC. In four patients, serous
detachment recurred (Cases 1, 8, 11 and 14).
Case 1 had CCSC in one eye that occurred in September
2003. After HP detection, antibiotic treatment was started,
and the serous detachment resolved completely after two
Table 1 - The results of the follow-up of 17 patients (18 eyes) diagnosed with central serous chorioretinopathy (CSC)
who were screened and treated for gastric infection with Helicobacter pylori (HP).
Patient Gender
Age
(years) Eye
Duration of disease
(months)
Gastric
Symptoms
Test for H.
pylori
Baseline
BCVA
Last follow- up
BCVA*
Duration of
follow- up (months)
1 M 56 L 36 + + 20/40 20/30 27 {
2 M 46 L 13 + + 20/80 20/50 27
2 M 46 R 6 (multiple recurrences) + + 20/200 20/30 27
3 M 56 L 6 (recurrence at 3 months) + + 20/80 20/20 27
4 M 42 R 6 + + 20/30 20/20 19
5 M 42 R 6 + + 20/80 20/20 13
6 M 31 L 12 - + 20/50 20/50 13**
7 F 50 R 6 + + 20/100 20/30 13
8 M 43 L 6 + + 20/30 20/20 12{
9 M 36 R 6 + + 20/50 20/20 9
10 M 45 R 36 + + 20/200 20/80 9
11 M 30 R 6 (recurrence at 3 months) - + 20/40 20/25 9{{
12 M 37 R 6 - + 20/60 20/25 9
13 M 55 R 6 + + 20/40 20/25 6
14 M 37 L 6 (recurrence at 3 months) + + 20/400 20/25 6{{
15 F 45 R 6 - - 20/30 20/30 ---
16 M 40 L 6 - - 20/50 20/50 ---
17 F 43 L 6 (recurrence at 3 months) - _ 20/80 20/20 ---
*The baseline visual acuity was 20/98 (logMAR = 0.53 standard deviation [¡] 0.28); the final visual acuity was 20/31 (log MAR 0.16 ¡0.17)
{(p=0.001) paired Student’s t test (for patients 1-14)
{Recurrence with serous detachment. Second biopsy positive. Retreated with improvement of serous detachment.
**Persistent serous detachment treated with laser photocoagulation
{{Recurrence after anti-HP drug therapy and a negative gastric biopsy for HP. Patient treated with laser photocoagulation.
{{Recurrence three months after successful treatment with anti-HP drug therapy. The second biopsy was HP positive, but the patient requested to be
treated with both anti-HP medication and photodynamic therapy.
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months (Figure 1). This patient experienced a recurrence
after 20 months and again tested positive for HP. After
retreatment, the serous detachment resolved. Case 3 was
positive for HP after the first treatment and underwent
retreatment. The patient experienced a complete resolution
of the serous detachment one month after the treatment
ended. All of the other patients experienced resolution of
their serous detachment after the first month of treatment
except Case 6, who required laser photocoagulation. Case 2
had bilateral serous detachment but no recurrence during
the 27 months of follow-up (Figure 2). Case 4 (Figure 3),
Case 5 (Figure 4), Case 13 and Case 14 had leaks near the
fovea, precluding regular laser treatment. Case 6, despite
testing positive for HP, did not improve after antibiotic
treatment and was referred for laser photocoagulation of the
leakage site. Case 11 experienced complete resolution of the
serous detachment after treatment with antibiotics but
experienced a CSC recurrence two months later. The gastric
biopsy was negative for HP, and the patient was treated with
laser coagulation. Case 9 experienced a serous detachment
recurrence seven months after successful treatment and was
subsequently found to have HP infection. The serous
detachment resolved after HP retreatment, and the patient’s
visual acuity improved from 20/40 to 20/20. In Case 14, the
serous detachment resolved but recurred after five months.
The second biopsy was HP positive, but the patient requested
treatment with both anti-HP medication and photodynamic
therapy, which was successful. The mean baseline visual
acuity was 20/98 (logMAR = 0.57¡0.28). The mean final
visual acuity was 20/31 (log MAR 0.16¡0.17) and differed
significantly from baseline (p,0.001).
DISCUSSION
To our knowledge, this is the first study in the literature
that treated HP in chronic cases of CSC and reported
improvement following an evaluation of BCVA and an OCT
examination. A similar study was performed in 2002 (10);
however, in that study, HP was not eradicated, the sample
size (16 eyes) was smaller than the current study (18 eyes),
and improvements in BCVA and OCT were not evaluated.
A French study found HP to be significantly more
prevalent in patients diagnosed with CSC than in the
normal population (11). In our study, a higher incidence of
Helicobacter pylori infection (82.35% - 15 patients and 18 eyes)
was found than the previously reported prevalence in
southern Brazil (63%) (18,19). Interestingly, 13 of 14 patients
showed improvement of CCSC following treatment for HP.
However, one of these cases recurred, and laser photo-
coagulation was required after a negative gastric biopsy. In
three patients, CCSC recurrence was associated with the
recurrence of HP infection, and serous detachment resolved
upon anti-HP retreatment in two of the cases; in the third
case, the patient asked for both photodynamic therapy and
anti-HP medication. In most of the responding cases, serous
detachment resolved within one month after antibiotic
treatment. One previously reported case of CCSC improved
clinically when the gastric infection was eradicated, and
recurrences of CCSC in this patient were associated with the
return of the bacterial infection (9). The recurrence rate of
27% (5 of 18 eyes) indicates that it is a frequent problem
associated with CSC, and this has been previously reported
(3,5).
Recently, a decrease in the subretinal fluid reabsorption
time was demonstrated in a group that received anti-HP
treatment compared to a control group (16).
HP chronically infects the gastric mucosa of more than
half of the human population (20). However, only 10-20% of
HP-infected patients develop known gastrointestinal com-
plications, such as peptic ulcer, gastric cancer and MALT
lymphoma, during their lifetime (21). The clinical outcome
of HP infection is determined by a complex interaction
between the bacterium and the host (22). HP has also been
associated with extra-gastric disorders, including a strong
association with idiopathic thrombocytopenic purpura and,
to a lesser degree, iron deficiency anemia, cardiovascular
disease and atherosclerosis (23). The explanations proposed
for these observed associations involve one or more
mechanisms with direct pathogenic effects, including
molecular mimicry between host and Helicobacter pylori
antigens, the chronic release of inflammatory mediators,
malabsorption and the abnormal production of vasoactive
substances (20). Indeed, Helicobacter pylori infection may
alter vascular function by increasing endothelin 1, inducible
nitric oxide synthase and nitric oxide, which may affect a
condition such as CSC (24,25). Although all of these data
suggest that HP infection is a systemic disease, we found
Figure 1 - Serous detachment in the macular region (A) that was
suggestive of CSC and subsequently confirmed with OCT (B).
Diffuse hyperfluorescent spots in the macular region and a
number of leaks were observed upon fluorescein angiography
imaging (C-D). Fundoscopy (E) and OCT imaging (F) indicated
resolution of the serous detachment. The macular leaks were
found to be diminished using fluorescein angiography, but the
hyperfluorescent spots persisted (G-H).
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only one case with bilateral CCSC among HP-positive
patients. However, if we were to evaluate angiogram
abnormalities in the contralateral eye, they would be present
in a significant percentage of patients (3). Another hypoth-
esis is that the medications used to treat HP infection
interfere with cortisol metabolism; for example, a decrease
in systemic cortisol levels was found after the use of
clarithromycin (26). One interesting finding of this research
is that 78.5% of the HP-positive patients and 64.7% of all
patients had gastric symptoms. This was previously noted
by other authors but was not observed in other studies
(1,2,6-13,27).
We evaluated the initial BCVA, final BCVA and complete
resolution of fluid by OCT and fluorescein angiography.
The OCT examination is particularly important in CCSC
cases because RPE and photoreceptors may be damaged,
and BCVA may not be the best parameter to evaluate the
possible benefits of HP treatment, as stated by other authors
(28).
This study was limited by its design. The retrospective
analysis of a multifactorial condition with a considerable
potential for spontaneous resolution, such as CCSC, is
problematic. Additionally, the high prevalence of HP
infection in the general population is another potential
confounding factor to be considered in a retrospective study
with a lack of controls. The observed changes in the macular
pathology may simply be due to chance or placebo effects or
even indirectly to changes in the emotions of the patients
with HP infection. However, the natural history of CCSC
observed in practice is different from that reported in this
study. Additionally, our findings suggest the possibility that
HP infection plays a role in the outcome of patients with
CCSC: serous detachment generally improved shortly after
initiating HP eradication treatment; the recurrence of CCSC
often coincided with the recurrence of HP infection; and the
retreatment of recurrent infection led to the resolution of
recurrent serous detachment.
Our findings suggest that HP infection may be present in
many CCSC patients and that eradication therapy may have a
favorable effect on the outcome of the disease. Due to the
multifactorial causes of CCSC, the possibility of spontaneous
regression and the high prevalence of the infection in the
general population, prospective and masked clinical trials are
necessary to confirm that treatment for HP infection may
benefit patients with CCSC. Such a suggestion was pre-
viously made by Abreu et al. in 2008 in their reply (29).
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Figure 2 - Fundoscopy demonstrated serous detachment in the lower temporal region (A) of the left eye near the vascular arch and just
below the fovea, although the detachment was better observed using OCT (B). Fluorescein angiography showed peripapillary
hyperfluorescence (C-D). The serous detachment improved after anti-HP treatment, and the leaks were found to be diminished (E-H).
Fundoscopy revealed serous detachment in the papillomacular bundle of the right eye (I). Serous detachment was observed using OCT
from the nasal region to the fovea of the right eye (J). Fluorescein angiography showed peripapillary hyperfluorescence (K-L). Serous
detachment improved after anti-HP treatment, and the leaks were found to be diminished (M-P).
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